肌少症定义与诊断修订版欧洲共识
欧洲老年人肌少症工作组(EWGSOP2)于2018年更新2010年肌少症定义,以低肌力为核心特征、低肌量与肌质量确认诊断、差体能提示严重肌少症,并更新临床算法与清晰切点,旨在促进早期识别与治疗。
要点
- 肌少症是终身不良肌肉改变所致的肌肉疾病(肌肉衰竭)。
- 以低肌力为核心特征,低肌量与肌质量用于确认诊断。
- 差体能提示严重肌少症,并给出清晰测量切点。
核心结论
- EWGSOP2更新共识旨在提高肌少症意识及其风险认知,呼吁医护人员对高危患者采取行动促进早期发现与治疗。
- 肌少症是终身不良肌肉改变累积所致的肌肉疾病(肌肉衰竭),在老年人中常见但也可较早发生。
研究设计与样本
- 欧洲老年人肌少症工作组(EWGSOP2)于2018年初召开会议,基于过去十年科学和临床证据更新2010年原始定义。
主要发现
- EWGSOP2聚焦低肌力作为肌少症关键特征,用低肌量和肌质量检测确认诊断,并将差体能确定为严重肌少症的指示。
- EWGSOP2更新了可用于肌少症病例发现、诊断与确认、严重程度判定的临床算法。
- EWGSOP2提供了识别和表征肌少症的变量测量的清晰切点。
关键数值与推荐
- 低肌力为肌少症关键特征,低肌量和肌质量用于确认诊断,差体能提示严重肌少症。
- EWGSOP2提供识别和表征肌少症的变量测量的清晰切点。
临床怎么用
- 医护人员应对肌少症风险患者采取行动,促进早期发现和治疗。
- 临床可使用EWGSOP2更新的算法进行肌少症病例发现、诊断与确认及严重程度判定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. OBJECTIVES: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. RECOMMENDATIONS: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. CONCLUSIONS: EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
引用
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019. PMID: 30312372. doi:10.1093/ageing/afy169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。